Smith & Nephew PLC (SNN)
25.01
+0.08
(+0.32%)
USD |
NYSE |
May 08, 16:00
25.01
0.00 (0.00%)
After-Hours: 20:00
Smith & Nephew Enterprise Value: 13.48B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 13.48B |
| May 06, 2024 | 13.40B |
| May 03, 2024 | 13.42B |
| May 02, 2024 | 13.27B |
| May 01, 2024 | 13.14B |
| April 30, 2024 | 13.13B |
| April 29, 2024 | 13.34B |
| April 26, 2024 | 13.27B |
| April 25, 2024 | 13.02B |
| April 24, 2024 | 13.32B |
| April 23, 2024 | 13.42B |
| April 22, 2024 | 13.23B |
| April 19, 2024 | 13.01B |
| April 18, 2024 | 13.08B |
| April 17, 2024 | 13.04B |
| April 16, 2024 | 12.99B |
| April 15, 2024 | 12.99B |
| April 12, 2024 | 12.97B |
| April 11, 2024 | 13.30B |
| April 10, 2024 | 13.23B |
| April 09, 2024 | 13.36B |
| April 08, 2024 | 13.23B |
| April 05, 2024 | 13.28B |
| April 04, 2024 | 13.22B |
| April 03, 2024 | 13.34B |
| Date | Value |
|---|---|
| April 02, 2024 | 13.19B |
| April 01, 2024 | 13.31B |
| March 28, 2024 | 13.67B |
| March 27, 2024 | 14.10B |
| March 26, 2024 | 13.98B |
| March 25, 2024 | 13.88B |
| March 22, 2024 | 14.04B |
| March 21, 2024 | 13.98B |
| March 20, 2024 | 14.13B |
| March 19, 2024 | 14.36B |
| March 18, 2024 | 14.24B |
| March 15, 2024 | 14.39B |
| March 14, 2024 | 14.60B |
| March 13, 2024 | 14.74B |
| March 12, 2024 | 14.82B |
| March 11, 2024 | 14.80B |
| March 08, 2024 | 14.67B |
| March 07, 2024 | 14.62B |
| March 06, 2024 | 14.57B |
| March 05, 2024 | 14.22B |
| March 04, 2024 | 14.17B |
| March 01, 2024 | 14.13B |
| February 29, 2024 | 14.17B |
| February 28, 2024 | 14.14B |
| February 27, 2024 | 14.81B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.76B
Minimum
Sep 27 2022
24.20B
Maximum
Feb 20 2020
17.44B
Average
17.23B
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 261.99B |
| Adaptimmune Therapeutics PLC | 124.57M |
| Biodexa Pharmaceuticals Plc | -3.200M |
| Verona Pharma PLC | 971.86M |
| NuCana PLC | -13.68M |
Enterprise Value Related Metrics
| Earnings Yield | 2.41% |
| Operating Earnings Yield | 6.04% |
| Normalized Earnings Yield | 2.407 |